Trial Profile
Alemtuzumab in multiple sclerosis: long-term follow-up (10.1 years) of the early cohorts
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Feb 2016
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- 26 Feb 2016 New trial record